secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2026-09-22T12:05:08+00:00
Accession:  0001140361-26-037298
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech publishes Phase 2 VERSATILE-002 results in JAMA Oncology; mOS 39.3 months in ICI-naive HNSCC
--------------------------------------------------------------------------------

- mOS of 39.3 months for CPS≥1 ICI-naive patients vs 17.9 months for pembrolizumab SOC.
- ORR 36% vs 19% published for pembro; 13.8% Grade≥3 TRAEs vs 17%.
- PIPE financing of up to $22.3M led by Nant Capital; NantWorks gets one-year exclusive license negotiation right for PDS0101.
- Company prioritizes PDS0301 in mCRC and pursues partnership for PDS0101.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126037298/0001140361-26-037298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126037298/ef20082545_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-037298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer